November 28, 2014 Enigami Newsletter

Enigami Medical Cannabis, LLC (a subsidiary for Enigami Systems, Inc.)

Enigami continues to entertain “R & D” proposals for entities interested in developing condition specific medical cannabis medications.

Enigami is interested in partnering with a limited number of Dispensaries and Clinics who wish to be national treatment models for medical cannabis. As the medical cannabis field moves toward medical legitimacy we want to be in the mix.

For folks who are in the process of submitting clinic and dispensary applications for the various medical cannabis states Enigami will consider LOI’s to accompany the applications. In some cases Enigami can offer generous advertising allowances for new businesses establishing themselves as clinics and dispensaries seeking a significant difference in treatment resources – those that help patients determine the appropriate medications(s) for their treatment.

On some Enigami sites you will soon notice a “How to Register” video which also serves as a comprehensive FAQ resource. We’re always improving our products, generating meaningful patents, and trademarks.

Clif Croan spoke on the Dr. Diane Dike Radio Show, “Picking the Right Medical Cannabis For Your Medical Treatment”, joined the Board at the National Association of Cannabis Based Medicine , and was elected Chair (as a gubernatorial appointee) of the (Colorado) Disability Benefit Support Contract Committee . Most of the Enigami staff are heavily involved in community service as is the company itself. A nice lead in for our pro bono Veterans study…

“Do Veterans with PTSD Benefit from Medical Cannabis?” – an ongoing National Study

Kudos to Dr. Gary Miller, one of the study principals, for the Exclusive Ben Swann Video Interview: Dr. Gary Miller Says Veterans With PTSD Need Access To Cannabis Dr. Miller, always meaningfully contributing to the community, was elected to his local school board. Congratulations !

Bill Graf and Clif Croan manned a booth, for the study, at the November 8 Denver Veterans Day Festival at Denver’s Civic Center Park, near the State Capitol. It was a huge event and there were about 5-10,000 veterans. ttp:// Bill Graf is constantly reaching out to various Vet advocacy organizations and is heavily committed to the worldwide community by his “hands on” philanthropic work in Haiti, several African nations, and southeast Asia.

Thank you ! to ML Mathre and Al Byrne, study members, for having made innumerable pitches for the study at more events than can be listed. What dedicated Vets they are ! Dr. Uma Dhanabalan, the study PI, continues her advocacy and has made numerous presentations at national conferences for the Vet study. She’s a Diamond !

Due to hosting problems on our website (2nd time) we were off line twice this month for a few hours. We no longer host our site with that organization. Problem solved.

A new informational brochure is available on the study website:

Please contact the VA to support new legislation enabling them to look at medical cannabis treatment for PTSD. A call to Colorado’s Rep. Polis office wouldn’t hurt either. Ask for Stuart Feinhor.

As always please “spread the word” about the study…the VA and mainstream media sure won’t ! And for all the organizations disseminating information about the Vet study…Thank You !

Have a Happy, Safe, and Joyful Holiday Season !

September 22, 2014, Enigami Newsletter

Our development team at Crank211, LLC have evolved into close friends and co-workers. Despite their best efforts to avoid service disruption Microsoft ‘s “Azure” had a severe hiccup in service the past few weeks. If you encountered difficulties in your web services MIcrosoft may be the culprit.

The “Marijuana for Medical Professionals” conference on Sept. 9-11, 2014, in Denver, was a HUGE success. Many thanks to Ms. Montemayor, of Healthy Choices Unlimited for putting on the most professional medical cannabis conference to date. We can’t wait to attend next year.

Clif Croan, of Enigami, will be doing a radio interview with Dr. Diane Dike, Oct. 10, 2014, about the importance of patients being able to understand the medical cannabis products contents and how they relate to the conditions they’re treating:

Enigami Medical Cannabis, LLC (EMC) will be “tossing it’s hat into the ring” at the Marijuana Tech Start Up Competition, in Denver, the weekend of Sept. 26. EMC will only be accepting proposals on the future of the database which defines the relationships between the cannabinoid combinations and the qualifying conditions.

“EMC” has entered into a limited number of agreements to serve as R&D to large grow operations both domestically and abroad. EMC will furnish the information for product specifications to a very small number of growers/manufacturers.

“Brownie Points” – we all love ‘em, right ? A number of Dispensary and Evaluation clinics have signed LOI’s to provide EMC patient medication/symptom tracking (to determine the appropriate medications for treatment) in applications for state licenses to open. Good luck with the applications folks ! EMC looks forward to working with you !

Lastly, EMC has submitted two research applications to the State of Colorado Medical Marijuana Research Grant Program (RFA #1353). EMC and Healthy Choices (HCU Education LLC) teamed together for a study entitled: “Use of urine neurotransmitter markers in determining appropriateness of cannabis for chronic pain patients”. In the second instance EMC has teamed with the Colorado Cross Disability Coalition to research: “A Correlational Study of Medical Cannabis Cannabinoids Efficacy in the Treatment of the Colorado Qualifying Conditions”. Our advocacy position for the Colorado disability community is to assess the community’s needs in relation to the Colorado Department of Health and Environment’s Medical Marijuana Registry. Tragically the State has failed to allow representation of the Colorado disability community in the various Boards relating to the use of Medical Cannabis in Colorado. EMC is also exploring research needs in Uruguay and Europe.

“Veterans, PTSD, and Medical Cannabis” – the national study inviting 10,000 participants is cruising along and we would appreciate the advocacy of anyone involved in advancing Veterans treatment options through the findings of this valuable study.
Not a word in answer to our communications from the Veterans Health Administration.

Dr. Gary Miller, a senior account specialist with Enigami based in Arizona, will be doing a radio interview on Liberty Radio, catch up to Dr. Miller and his comments about the need for Veterans advocacy:

August, 14, 2014, Enigami Newsletter

Thanks to everyone who has signed up for Enigami Medical Cannabis subscriptions ! The first month has been fantastic.

It has been a delight to hear from everyone across the Nation. We wish you good health ! Here are a few notes about what we are up to in the next month or so.

Conferences Scheduled:

September 9, 10, 11, Enigami Medical Cannabis, LLC will be exhibiting at the Denver Medical Marijuana Professionals Conference.

Sept. 11, 2014, Enigami Medical Cannabis, LLC will be present in Minneapolis, Minnesota for a stakeholders conference at the Thompson Hall law firm offices.

Sept. 26th, Enigami Medical Cannabis, LLC will be attending and presenting at the Marijuana Tech Start Up Competition the weekend of September 26th, in Denver.

We’ll also be in attendance at the (Colorado) Marijuana Scientific Advisory Council meetings scheduled through the next few months. If you are in Denver – drop in and watch the process as Colorado decides how to research medical cannabis. Another state with an outstanding approach to medical cannabis treatment is Minnesota. Here is a link to the Minnesota regs: . Minnesota’s inclusion of: “How will the state track the effectiveness and safety of medical cannabis?” and “What are the obligations of patients and health care providers participating in the state’s medical cannabis program?”… are great enhancements to the legitimacy of Dr/Pt relationships, clinical care, and serious Medical Cannabis treatment. They have good thoughts for all the state’s supporting innovations in medical cannabis treatment.

Enigami has opened up a “Ben & Jerry’s” type of competition. We are interested in proposals concerning our knowledge base which is defining the relationships between the cannabinoid combinations (or products) and the various conditions. This knowledge is largely absent from medical cannabis AND the medical field. In the future such knowledge will help educate physicians about recommending, or prescribing, medical cannabis products. It will empower Consumers. This knowledge could be used to guide product development by savvy medical cannabis product developers. It could be used to guide Federal policy, specifically the Veterans Health Administration, and State policy. Should this de-identified aggregate information be published on a Bhutanese mile marker so it may be discovered by an intrepid traveler ? Should a group of medical cannabis stakeholders decide how to disseminate the information ? Should a note be placed in a bottle and thrown out to the dark blue sea ? We’ll accept any creative proposals – even in crayon !

Sign up for the Veterans study is going gangbusters too !!! Some of you persevered through an obscure website glitch dealing with website security…THANK YOU !!!

There are downloadable Posters and Brochures available on the website: please feel free to use to “get the word out”.

Please submit any support tickets or questions to:

Have you noticed the news blackout of this study – even in the medical cannabis and Veterans communities ? We’d appreciate hearing your comments on why some folk are trying to suppress medical cannabis research for Veterans with PTSD. Drop a note to us at:

Please “spread the word” about the Veterans study. We want to finish up the research 10,000 strong.

Scientific Study Factoid for the Day – Observational studies: going beyond the boundaries of randomized controlled trials

– Wenying Yang, Alexey Zilov, Pradana Soewondo, Ole Molskov Bech, Fawzia Sekkal, Philip D. Home (

Abstract: The term observational study describes a wide range of study designs including prospective and retrospective cohort studies, case-control studies, and cross-sectional studies, a defining feature of which is that any intervention studied is determined by clinical practice and not the protocol. Data from large, prospective observational studies provide information about the safety and efficacy of medicines in daily clinical use. Such observational studies are generally carried out once a medicine has received approval from regulatory agencies. Observational trials have inherent limitations in terms of their susceptibility to bias and confounding, restricting their ability to define causality. However, their strengths include that they reflect daily clinical practice more closely than randomized controlled trials (RCTs), both in terms of the heterogeneous patient populations that are included, and the medical interventions that they receive. Therefore, observational trials can provide clinically relevant information that is not necessarily provided by RCTs. Given the limitations of an observational study approach, it is important to optimize their study design to maximize their validity, and thus, in particular, known causes of bias and confounding should be measured. Medical investigators, health authorities, and the pharmaceutical industry all have important roles to play in designing, approving, and performing observational studies.


“The future of MMJ treatment is dependent on several issues: physicians must establish legitimate, bona fide, physician/patient relationships, patients must have a method of determining the best medication for their unique symptoms, and clinical outcomes for ongoing treatment must be obtained to validate the field of medical marijuana. These are the three areas our company focuses on.” (C. Croan)

The anti-medical marijuana lobby is effective so let’s recognize how they are effectively undermining the medical marijuana industry:

 They have raised the issue of whether MMJ dr/pt relationships are valid, legitimate or even professional.
 The MMJ “evaluation” does not employ “MMJ care” it only uses “MMJ evaluation” in other words “care” or “treatment” is missing in the MMJ treatment model.
 Anti-mmj legislators have adroitly maneuvered MMJ physicians into performing evaluations only – with no follow up care. The MMJ docs thought they were winning a major point and they would cash in on evaluations. This robs the MMJ industry from obtaining positive clinical outcomes.
 Currently there is no vehicle to use aggregate data to indicate whether MMJ actually works as a treatment. “Pharma” trials do that but MMJ has entered the market essentially untested.

The current MMJ care model dooms the field.

In regard to physician/patient relationships the state legislators the author is familiar with intended only for a physician to perform the MMJ evaluation. It is clearly specified that a physician’s assistant or other professional may not perform the evaluation and have the doctor sign off – it’s flirting with disaster to operate against the legislative intent and administrative policy. We don’t need people in the field who cut corners. But they won’t be around long without licenses or clinics as we are seeing.

If a clinic takes your money for an evaluation…shouldn’t they reimburse your money if they dropped the ball about an aspect of their compliance and you were NOT provided a legitimate evaluation? Should you have received a refund from the clinic? This makes some clinics, or organizations look, pretty…mercenary.

Oh, and to the physician who related to the author, “Since PTSD is psychic pain I’m going to recommend that condition for MMJ because technically it’s chronic pain and PTSD isn’t authorized”. Bullshit, that’s dishonest.

Anyone cutting legal corners in the MMJ field is doing EVERYONE a disservice.

Failure to follow up in medicine is contradictory to the mainstream medical care model which is called “evidence based medicine”. After all – who would recommend a Schedule I substance and not follow up on the effect for treatment?

In every Medical Practice Act, in every state where MMJ is authorized, there lies the seed of one of the next regulations. Ever physician is actually required, now, to follow up with the patient about the medical intervention (the MMJ recommendation). Our prediction at Enigami is that legitimate follow up will be increasingly enforced by the regulatory agencies. At the time of this writing four states mandate follow up.

But what is it the regulatory agencies are going to require? Evidence based medicine. Wikipedia defines it like this: “Evidence based medicine aims to apply the best available evidence gained from the scientific method to clinical decision making.” In other words there needs to be some type of legitimate method to “follow up” or to monitor whether the medical intervention actually works. Okay, that’s just good medicine and good for the consumer.

Currently, in those states where there is no follow up care – we obtain no clinical evidence of whether MMJ actually is effective. Grrrrr.

The Colorado Medical Practice Act is pretty typical of the different States and partially relies on case law. Colorado’s Act quotes case law defining medical practice as not being a discrete single event. Yet in the MMJ care model it stops at a single event – evaluation. It’s true that in many areas of medicine consumers may go to a specialist who evaluates us and refers us on for ongoing needs – and therein is the key – MMJ evaluators have no viable follow up referrals because they don’t exist. How many primary care doctors will perform the follow up? There are a few MMJ doctors who perform minimal follow up and still more physicians who are concerned about the question of having a legitimate physician/patient relationship. Follow up care would go a long way to enhancing the MMJ care model. In fact performing follow up care, “evidence based medicine”, will help patients determine the best medication.

But there’s another great benefit to follow up care besides just practicing legitimate medicine. It can provide clinical outcomes which legitimize the entire field of medical marijuana. The “evaluation only model” was considered a win by physicians in legislation. So I say, “Congratulations, you’ve robbed the field of MMJ from establishing itself as legitimate by not being able to show hard research outcomes!”

Help is on the way though. Pioneering MMJ legislators are making legitimate follow up mandatory. It’ll be a short step to collecting those outcomes and being able to quote hard data instead of relying on anecdotal success stories. Instead of saying, “it MIGHT shrink tumors” we’ll get to say, “in an multi-year study involving 350,000 MMJ patients – those with such and such tumors showed reduction in size (etc.)”

The lack of a legitimate medical marijuana care model concerns us so here is what we did.

We created Enigami Systems, Inc., to uses outbound email inquiries (or other methods of media communication) to follow up and inquire about a client’s unique symptoms and how they are responding to a specific MMJ medication which we also track. The information, helps determine which medication is the best used to diminish, or contain, distressing symptoms. The outbound inquiries come from our online portal where the individual’s personal health record exists. We can monitor with whatever frequency is desired which makes a heckuva medical record but after all is said and done it beats the pants off of ANY mainstream medicine follow up.

Oh, our aggregate “outcomes” legitimize the MMJ field’s effectiveness